If this trend continues linearly, the risk reduction would be substantial over 20 or 30 years. The Work Group also places higher value on increased pill burden, more clinic visits, electrolyte abnormalities, hypo- tension, syncope, injurious falls, and AKI that may be caused by targeting an SBP <120 mm Hg. However, intensive SBP lowering in CKD patients did not cause more serious adverse events, orthostatic hypotension, syncope, or injurious falls than targeting SBP <140 mm Hg in SPRINT. The Work Group places lower values on the higher risks of mild AKI, hyperkalemia, and hypokalemia seen in the intensive SBP lowering in CKD patients because they are largely mild, transient, and manageable. We found no informative studies of how patients with CKD would balance these potential bene ts with potential harms. The adoption of an SBP target <120 mm Hg is an ideal topic for shared decision-making between individual pa- tients and clinicians. There is likely to be marked variability in how individual patients weigh and value the potential bene ts and harms of intensive BP control. This may vary with age, culture, number of drugs (both BP-lowering and other drugs), and other factors. Decision aids to support shared decision-making are available on the online version of this guideline (see link to MAGICapp at https://kdigo.org/ guidelines/blood-pressure-in-ckd/). These aids are based on the evidence syntheses compiled by the ERT that were used to develop the guideline and can be used online or to generate printable summaries of the evidence relating to each decision (e.g., differences in absolute mortality or in AKI per 1000 patients with standard vs. intensive SBP target). Resource use and costs. The implications for resource uti- lization for standardized of ce BP measurement, as recom- mended in this guideline, are discussed in Chapter 1. 